HIVUC stands for HIV-associated uveitis, which refers to an inflammation of the uvea, the middle layer of the eye, in individuals infected with the human immunodeficiency virus (HIV). It is a condition characterized by the presence of anterior uveitis, an inflammation primarily affecting the front portion of the uvea, which includes the iris and the ciliary body.
HIV-associated uveitis typically occurs as a result of immune dysregulation caused by HIV infection. The condition often manifests as redness, pain, blurred vision, sensitivity to light, and the presence of floaters in the affected eye. Occasionally, both eyes may be involved, but it predominantly affects one eye.
The diagnosis of HIVUC is based on a comprehensive eye examination conducted by an ophthalmologist, which may include a slit-lamp examination, fundoscopy, and other diagnostic tests. Additionally, a thorough medical history and laboratory investigations may be performed to confirm the underlying HIV infection.
The management of HIVUC includes both local and systemic treatments. Local therapy commonly involves the use of corticosteroid eye drops to reduce inflammation, while systemic treatment focuses on managing the underlying HIV infection with antiretroviral drugs. Other medications, such as immunosuppressive agents, may be necessary in more severe cases.
Regular monitoring and follow-ups are essential for individuals with HIVUC to evaluate treatment response, adjust medication doses, and manage potential complications, such as elevated intraocular pressure or cataracts. With appropriate medical intervention, the prognosis for HIVUC is generally favorable, although recurrent episodes may occur.
